Signal transduction: aspirin, ubiquitin and cancer.
Wilkinson
Keith D
KD
D001241:Aspirin; D000074749:Deubiquitinating Enzyme CYLD; D006801:Humans; D051550:I-kappa B Kinase; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D015398:Signal Transduction; D013577:Syndrome; D047992:TNF Receptor-Associated Factor 2; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*; D025801:Ubiquitin / Q000378:metabolism*
D016328:NF-kappa B; D011506:Proteins; D047992:TNF Receptor-Associated Factor 2; D025521:Tumor Suppressor Proteins; D025801:Ubiquitin; D017346:Protein Serine-Threonine Kinases; C496559:CHUK protein, human; D051550:I-kappa B Kinase; C496560:IKBKB protein, human; C496565:IKBKE protein, human; C409984:CYLD protein, human; D000074749:Deubiquitinating Enzyme CYLD; D001241:Aspirin